Clinical trials: Kidney Disease
Nephrogenic Systemic Fibrosis, Renal Insufficiency
Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following OptiMARK Injection
The objective of this study is to prospectively monitor the incidence of adverse drug reactions, specifically NSF during routine use of gadoversetamide in a large number of patients with moderate renal insufficiency (eGFR 30-59)…
- Trial name
- SHERLOC (NCT00811863)
- Where
- United States
- Sponsor
- Guerbet
Glomerulonephritis, Membranous
Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy
The main clinical study will be a randomized, double-blind, placebo-controlled, long term study involving a 100 week treatment period.
- Trial name
- NCT01762852
- Testing
- Belimumab 10 mg
- Where
- 30 sites in United States, Australia and 8 more
- Sponsor
- GlaxoSmithKline
Anemia, Chronic Kidney Disease
Peginesatide for Anemia in Chronic Hemodialysis Patients
The purpose of this study is to evaluate the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of multiple intravenous doses of peginesatide in participants with chronic kidney disease (CKD) who are on hemodialysis.
- Conditions
- Anemia, Chronic Kidney Disease, Chronic Renal Failure
- Trial name
- NCT00228449
- Testing
- peginesatide
- Where
- 14 sites in United States
- Volunteers
- 165 people
- Sponsor
- Affymax
End Stage Renal Disease, ESRD
Safety and Efficacy Assessments of NeoKidney® in ESRD Patients Treated With Short Daily Hemodialysis
The goal of this clinical investigation is to asses the safety and efficacy a new sorbent-based hemodialysis device, NeoKidney® in ESRD patients treated with short daily hemodialysis.
- Trial name
- FIH Caen (NCT06024135)
- Testing
- NeoKidney
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Nextkidney S.A.
Kidney Disease
An Evaluation of Aranesp® in Subjects With Anaemic Chronic Kidney Disease (CKD)
The purpose of this study is to assess if Aranesp® administered once every 4 weeks to chronic kidney disease subjects is safe and efficacious in maintaining haemoglobin levels greater than or equal to 100 g/L.
- Trial name
- NCT00124098
- Testing
- Aranesp® (darbepoetin alfa)
- Sponsor
- Amgen
Chronic Kidney Disease (CKD)
Observational Secondary Data Study Describing Treatment With Dapagliflozin Among Adult Chronic Kidney Disease Patients
The OPTIMISE-CKD CEE study design will create a real-world evidence platform that systematically leverages the routine data collection made by Investigators and will help obtain relevant insights from clinical practice.
- Trial name
- OPTIMISE-CKD (NCT06203704)
- Where
- 56 sites in Bulgaria, Croatia and 5 more
- Volunteers
- 1,086 people
- Sponsor
- AstraZeneca
Glucose Lowering
To Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients
To assess the pharmacokinetics of AZD1656, and its metabolite, in type 2 diabetes mellitus patients with varying degrees of renal impairment and to compare the results with those in patients with normal renal function.
- Trial name
- NCT01069926
- Testing
- AZD1656
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- AstraZeneca
Soft Tissue Injuries, Gouty Arthritis
AMPED Outcomes Registry of Post-ED Pain Management
Study aims to assess patient-recorded outcomes of pain control medications prescribed in the ER after visits for specific painful injuries/illnesses.
- Conditions
- Soft Tissue Injuries, Gouty Arthritis, Fractures, Ureteral Colic
- Trial name
- AMPED (NCT01626235)
- Where
- 11 sites in United States
- Volunteers
- 843 people
- Sponsor
- Radnor Registry Research, Inc
Carcinoid, Neuroendocrine
Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features
The primary purpose of the study is to determine if Seneca Valley Virus may be administered safely to patients with certain types of advanced cancer.
- Trial name
- NCT00314925
- Testing
- Seneca Valley Virus (biological agent)
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Neotropix
Renal Impairment
Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal Function
This study will evaluate the effect of various degrees of renal function on the pharmacokinetics and safety of ALKS 5461.
- Trial name
- NCT02508506
- Testing
- ALKS 5461
- Where
- 3 sites in United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Alkermes, Inc.
Autosomal Recessive Polycystic Kidney (ARPKD)
A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
To evaluate the pharmacodynamics and safety of tolvaptan in pediatric subjects with ARPKD
- Trial name
- NCT04782258
- Testing
- Tolvaptan Suspension, Tolvaptan Tablets
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 20 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Secondary Hyperparathyroidism
Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism
The purpose of this study is to characterize the safety and tolerability and efficacy of multiple ascending doses of etelcalcetide in hemodialysis patients for the treatment of secondary hyperparathyroidism (HPT).
- Trial name
- NCT01254565
- Testing
- Etelcalcetide
- Where
- 13 sites in United States
- Volunteers
- 87 people
- Sponsor
- KAI Pharmaceuticals
Locally Advanced or Metastatic Solid Tumors, NSCLC
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of enzelkitug when administered as a single agent and in combination with atezolizumab or pembrolizumab in adult…
- Conditions
- Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma
- Trial name
- NCT05581004
- Testing
- Enzelkitug, Atezolizumab, Pembrolizumab
- Where
- 32 sites in United States, Australia and 7 more
- Volunteers
- 165 people
- Sponsor
- Genentech, Inc.
Renal Cell Carcinoma
Real-world Treatment Patterns and Outcomes Among aRCC Patients on Cabozantinib or Axitinib in England
The present study will aim to describe and understand, in the real-world, the clinical characteristics, treatment patterns and outcomes of advanced renal cell carcinoma (aRCC) patients treated with cabozantinib or axitinib…
- Trial name
- NCT04637204
- Testing
- Cabozantinib, Axitinib
- Where
- United Kingdom
- Volunteers
- 1,540 people
- Sponsor
- Ipsen
Iron Deficiency Anemia Treatment, Chronic Kidney Disease(CKD)
Compare Efficacy/Safety of Repeat Doses of Ferumoxytol With Iron Sucrose in CKD Subjects With IDA and on Hemodialysis
The objectives of this study are to compare the efficacy and safety of repeat doses of intravenous (IV) ferumoxytol with IV iron sucrose for the treatment of IDA in subjects with hemodialysis-dependent CKD.
- Trial name
- NCT01227616
- Testing
- Ferumoxytol, Iron Sucrose
- Where
- 43 sites in United States, Canada and 1 more
- Volunteers
- 296 people
- Sponsor
- AMAG Pharmaceuticals, Inc.
Renal Insufficiency Chronic
A Trial of Hydroxynidone Capsules in Single-dose Administration for Patients With Renal Insufficiency
Hydronidone capsules are pyridinone-based small molecule compounds. Hydronidone has not been approved for commercial sale both domestically and internationally.
- Trial name
- NCT07262333
- Testing
- Hydronidone capsules
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Infection, Human Immunodeficiency Virus
Dolutegravir Renal Impairment Study
Dolutegravir (DTG, GSK1349572) is an integrase inhibitor being developed for the treatment of human immunodeficiency virus (HIV)-1 infection by GlaxoSmithKline (GSK) on behalf of Shionogi-ViiV Healthcare LLC.
- Trial name
- NCT01353716
- Testing
- Dolutegravir 50 mg
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Thrombosis
Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment
Assess the pharmacokinetics, safety, and tolerability of a single dose of BMS-986177 in participants with normal renal function and moderate to severe renal impairment.
- Trial name
- NCT03196206
- Testing
- BMS-986177
- Where
- 3 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Hypertension
EnligHTN IV Trial - Multicenter Sham-controlled RCT of Renal Denervation for Hypertension
The purpose of the EnligHTN IV clinical investigation is to demonstrate the safety and effectiveness of the EnligHTN™ Renal Denervation System in the treatment of subjects with drug-resistant uncontrolled hypertension.
- Trial name
- EnligHTN-IV (NCT01903187)
- Testing
- EnligHTN Renal Denervation
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Abbott Medical Devices
End Stage Renal Disease Requiring Hemodialysis
Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug
Patients whose kidneys are no longer able to work as they should and require treatment to filter wastes from the blood (hemodialysis) are at high risk for blood clots that form in blood vessels (thrombosis) blocking blood flow…
- Trial name
- RE-THINc ESRD (NCT04534114)
- Testing
- Fesomersen sodium (BAY2976217)
- Where
- 69 sites in United States, Belgium and 13 more
- Volunteers
- 307 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.